Marker Therapeutics Inc (MRKR)

[hanscott]

Impatient Trader-Deranged Market Syndrome is the only real reason I can come up with for being responsible for our share price dropping.

MRKR is hitting milestones (new CGMP facility up and running, half the clinical trial sites are up and running with some patients dosed already for AML PII. . .) and cash is not a problem.

And the data look reasonably good for the ALL study, although it's a small population (but cash, and timeline to PII/III ???). But at least it shows we have irons in the fire, and it shows Team MRKR isn't "out golfing" or goofing off on their XBOXes gaming all day:)

Imo, the markets have become more of a slot machine than investment vehicle for a Lot of people now days.

Especially with the cell-phone trading younin's (like my son) with all those "Robin Hood" apps out there now, and the REDDIT Gamblers - see r/GME, plus the impatient "opportunity costs" longs, etc, etc . . . . so long term, value, science-minded BAG-HOLDERS like us are a dying breed???

--------------------------------------------------------

1. The run-up to $3.60 in June might have been fueled in part by traders who then took profits? The float down then happened in part bc traders exiting and in part due to some newer longs figuring that, based on the time table for the AML PII, there was plenty of time to re-enter later?
-------------------------------------------------------

2. Re. the drop in SP after the 2ndQ report on August 10th PR:

AML Trial Milestones
a) Complete enrollment of 20 patients in main portion of Phase 2 trial in Q4 2021
b) Topline readout of Group 2 (active disease) in Q1 2022

Maybe this seemed like slow enrollment to some??? And again, suggested to "opportunity costs"-minded longs there would be plenty of time to re-enter later???

-----------------------------------------------------------

3) The drop in SP and then slow fall-off since the release of the:Nov 10 3rd Q Report.

Again, it's good to hear the following, but to SOME people's kids our enrollment pace might seem sluggish and they think there will be plenty of time to re-enter later ???

a) "We are pleased to announce that the first patients in Marker's Phase 2 AML trial have been dosed with study drug. Further, we are on track to enroll the first 20 patients of the trial in the fourth quarter, with the first data readout expected in the first quarter of 2022.

b) But also bear in mind they added two PII study trial sites as of the October update(now up to 12 trial sites out of 20 they hope to have for the study- as per the Nov 3rd Q report). So again, Team MRKR isn't exactly taking long siestas in the offices/labs/clinics.

--------------------------------------------------------

4) The data from the PR for the presentation Dec 11-14,yesterday.

Compare our results from are (only PI) 11 patients so far, compared to the charts below for Childhood and Adult survival rates post transplant for ALL.

Adults (three, 1 dropped out):
#4, 41yo, CR 47mo (4yr)
#11, 23yo, CR 10mo, Relapsed

Our childhood victims (<18yo, eight, 2 dropped out):
#2, 18yo CR 6mo, Relapse
#3, 18yo, CR 51mo (4.25yr)
#5, 13yo, CR 9mo
#7, 12yo, CR 48mo (4yr)
#8, 18yo, CR 46mo (~4yr)
#9, 12yo, CR 36mo (3yr)

a) Adult Survival Rates - Our patients are all high-risk Acute Lymphoblastic Leukemia (HR-ALL), so I guess would correspond to "advanced ALL" (orange line).

I have not yet had a chance to look at the video this chart apparently came from, which goes into "explain(ing) what CAR T cell therapy is, who it may help, what the treatment is like, potential risks and benefits, questions to ask your doctor, and more."

b) Failure in Childhood Acute Lymphoblastic Leukemia (ALL).: and they note "Childhood ALL Failure of remission-induction therapy is a rare but highly adverse event in children and adolescents with acute lymphoblastic leukemia."


Childhood ALL Survival Rates for:
a) B-Cell ALL in general vs Chemo only, b) B Cell-lymphoma related Donors did better than unrelated donors, c) T-Cell any type of donor ___ roughly 40-70% at ~3-4yrs.

So maybe in our tiny sample size, the times of CR are looking good, but for childhood ALL, it doesn't necessarily seem like our results are statistically significantly different enough yet on a 50-10 yr survival rate???

---------------------------------------------------

5) Our therapy is just "not sexy" enough ??? Which sounds ridiculous, but to those new to investing in this to the area, this might be a factor? Although you would think institutional investors would love it. . . who the fck knows "what goes on in every (person's) head"?

"[B]Because Marker does not genetically engineer its T cell therapies,[/B] we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, [B]compared to current engineered CAR-T and TCR-based approaches[/B], and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies."

-------------------------------------

So . . . on a slow boat to China we go? - and bring plenty of "Cough Syrup."